Login to Your Account

DOT’s No Fair? Epizyme Reeling; Phase I ‘Panic’ on Wall Street

By Randy Osborne
Staff Writer

Friday, November 15, 2013
Epizyme Inc.’s Phase I study, designed mainly to determine the safety of EPZ-5676, an inhibitor of the DOT1L histone methyltransferase (HMT) for the treatment of acute leukemia with rearrangements in the mixed lineage leukemia gene (MLL-r), ended up showing treatment effects in four of eight patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription